Oxurion Announces Second Amendment to Negma Funding Program
Oxurion Announces Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 25, 2023 8:30 am –...
Staff
154,112 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE25 JANUARY 2023 at 9.00...
Sosei Heptares Webinar Presentation for FY2022 Financial Results
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world...
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused...
Jasper Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
GENFIT Announces 2023 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical...
Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB) The...
InnovAge to Announce Fiscal Second Quarter 2023 Financial Results and Host Conference Call Tuesday, February 7, 2023
DENVER, Jan. 24, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2023 fiscal second quarter...
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...
For the 14th Year, Inovalon Provides Charitable Support to Local, National, And International Organizations
Long-standing, Employee-driven Support of Philanthropic Efforts Grows 20% Year-Over-YearBOWIE, Md., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Inovalon, a leading provider...
Hydreight Technologies Inc Begins Trading on the Frankfurt Stock Exchange
VANCOUVER, British Columbia and LAS VEGAS, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV:...
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative...
PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA
PharmAla Biotech believes that this is the largest export permit of MDMA granted to date by Health CanadaVANCOUVER, British Columbia,...
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple MyelomaSOUTH...
Petalfast Expands Portfolio Through Partnership with Cannabis Tincture Brand Yummi Karma
IRVINE, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Petalfast, a route-through-market platform for the cannabis industry, announced its partnership...
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the...
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
eGenesis Announces Knut Niss as Chief Technology Officer
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment...
Apexigen Announces Approximately $2.8 Million Private Placement Financing
SAN CARLOS, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN), a clinical-stage company focused on developing innovative...